Tag Archives: Momenta Pharmaceuticals

January, 2017

6 January
CSL and Momenta Announce Collaboration and License Agreement to Develop Fc Multimer Programs

CAMBRIDGE, MA — Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) and CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that they have entered into an exclusive research collaboration and worldwide license agreement to develop and commercialize Fc multimer proteins, including Momenta’s M230, a selective immunomodulator of Fc receptors, which is expected to enter the clinic …
Share

30 November
Momenta’s Humira Biosimilar Succeeds in Late-Stage Psoriasis Study

CAMBRIDGE, Mass., Nov. 29, 2016 (GLOBE NEWSWIRE) — Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that the confirmatory Phase 3 clinical study of M923, a biosimilar HUMIRA® (adalimumab) candidate developed in collaboration with Baxalta, now part of Shire plc, in patients with moderate-to-severe chronic plaque psoriasis, met its primary endpoint. The proportion …
Share

5 August
Momenta Halts Late-Stage Pancreatic Cancer Trial After Interim Analysis

CAMBRIDGE, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) — Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the Company has discontinued further accrual in its Phase 2 trial evaluating necuparanib in combination with Abraxane® and gemcitabine in patients with advanced …
Share

8 January
Mylan Partners with Momenta to Develop Six Biosimilar Products

HERTFORDSHIRE, England and PITTSBURGH, Jan. 8, 2016 /PRNewswire/ — Mylan N.V. (NASDAQ, TASE: MYL) today announced that it has entered into an exclusive global collaboration agreement with Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) to develop, manufacture and commercialize six of Momenta’s current biosimilar candidates, including Momenta’s biosimilar candidate, ORENCIA® (abatacept). Mylan …
Share

28 December
Baxalta and Momenta’s Humira Biosimilar Candidate Meets Primary Endpoint in PK Study

BANNOCKBURN, Ill. and CAMBRIDGE, Mass., Dec. 21, 2015 (GLOBE NEWSWIRE) — Baxalta Incorporated (NYSE:BXLT) and Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), today announced that M923 met the primary endpoint in a randomized, double-blind, three-arm, parallel group, single-dose study. The primary objective of the study was to evaluate the pharmacokinetics of M923 compared …
Share

16 April
Sandoz Receives FDA Approval for the First Generic Version of Teva’s Multiple Sclerosis Drug Copaxone

Today, the US Food and Drug Administration (FDA) approved the first generic version of Teva Pharmaceuticals’ top-selling multiple sclerosis drug Copaxone (glatiramer acetate injection). The agency approved Sandoz’s Abbreviated New Drug Application (ANDA) for once daily Glatopa 20 mg/mL, a generic equivalent of daily Copaxone 20 mg. Glatopa is now …
Share